Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

UroGen Pharma (URGN) Return on Invested Capital (2021 - 2025)

Historic Return on Invested Capital for UroGen Pharma (URGN) over the last 5 years, with Q3 2025 value amounting to 1.3%.

  • UroGen Pharma's Return on Invested Capital rose 44100.0% to 1.3% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.3%, marking a year-over-year increase of 44100.0%. This contributed to the annual value of 2.67% for FY2024, which is 17900.0% up from last year.
  • Per UroGen Pharma's latest filing, its Return on Invested Capital stood at 1.3% for Q3 2025, which was up 44100.0% from 1.82% recorded in Q2 2025.
  • In the past 5 years, UroGen Pharma's Return on Invested Capital ranged from a high of 20.68% in Q1 2022 and a low of 11.85% during Q4 2024
  • Its 5-year average for Return on Invested Capital is 1.74%, with a median of 1.16% in 2022.
  • Its Return on Invested Capital has fluctuated over the past 5 years, first plummeted by -199000bps in 2023, then soared by 162100bps in 2024.
  • UroGen Pharma's Return on Invested Capital (Quarter) stood at 4.68% in 2021, then skyrocketed by 122bps to 1.05% in 2022, then rose by 21bps to 1.27% in 2023, then crashed by -1032bps to 11.85% in 2024, then skyrocketed by 111bps to 1.3% in 2025.
  • Its Return on Invested Capital was 1.3% in Q3 2025, compared to 1.82% in Q2 2025 and 4.0% in Q1 2025.